UA80591C2 - C-6 modificated indazolilpyrrolotriazines, pharmaceutical composition upon their base and method of the treatment - Google Patents

C-6 modificated indazolilpyrrolotriazines, pharmaceutical composition upon their base and method of the treatment Download PDF

Info

Publication number: UA80591C2
Authority: UA; Ukraine
Prior art keywords: ester; carbamic acid; indazol; ethyl; pyrrolo
Prior art date: 2002-12-13

Application number

UAA200506891A

Other languages

English (en)

Ukrainian (uk)

Inventor

John F Kadow

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-13

Filing date

2003-12-12

Publication date

2007-10-10

2003-12-12 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-10-10 Publication of UA80591C2 publication Critical patent/UA80591C2/uk

Links

238000011282 treatment Methods 0.000 title claims abstract description 32
238000000034 method Methods 0.000 title claims description 44
239000008194 pharmaceutical composition Substances 0.000 title claims description 12
150000001875 compounds Chemical class 0.000 claims abstract description 111
150000003839 salts Chemical class 0.000 claims abstract description 18
201000010099 disease Diseases 0.000 claims abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
230000000694 effects Effects 0.000 claims abstract description 16
102000009465 Growth Factor Receptors Human genes 0.000 claims abstract description 11
108010009202 Growth Factor Receptors Proteins 0.000 claims abstract description 11
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 9
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 9
230000019491 signal transduction Effects 0.000 claims abstract description 6
-1 1-(2-thienylmethyl)-1H- indazol-5-ylamino Chemical group 0.000 claims description 194
150000002148 esters Chemical class 0.000 claims description 88
239000002253 acid Substances 0.000 claims description 45
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
125000000217 alkyl group Chemical group 0.000 claims description 28
125000003118 aryl group Chemical group 0.000 claims description 27
206010028980 Neoplasm Diseases 0.000 claims description 22
102000005962 receptors Human genes 0.000 claims description 21
108020003175 receptors Proteins 0.000 claims description 21
125000003107 substituted aryl group Chemical group 0.000 claims description 17
125000003710 aryl alkyl group Chemical group 0.000 claims description 14
239000003112 inhibitor Substances 0.000 claims description 13
239000002246 antineoplastic agent Substances 0.000 claims description 12
125000000547 substituted alkyl group Chemical group 0.000 claims description 12
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
108091000080 Phosphotransferase Proteins 0.000 claims description 10
102000020233 phosphotransferase Human genes 0.000 claims description 10
229940127089 cytotoxic agent Drugs 0.000 claims description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
230000001093 anti-cancer Effects 0.000 claims description 8
201000011510 cancer Diseases 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
239000002254 cytotoxic agent Substances 0.000 claims description 8
231100000599 cytotoxic agent Toxicity 0.000 claims description 8
150000004702 methyl esters Chemical class 0.000 claims description 8
JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 claims description 7
201000004681 Psoriasis Diseases 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
229940002612 prodrug Drugs 0.000 claims description 7
239000000651 prodrug Substances 0.000 claims description 7
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 6
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical group C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
239000003102 growth factor Substances 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 claims description 6
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
229960004316 cisplatin Drugs 0.000 claims description 4
GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 claims description 4
125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical group C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 3
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical group O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
108010092160 Dactinomycin Proteins 0.000 claims description 3
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 3
AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical class C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 3
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical group C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 3
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
108010069236 Goserelin Proteins 0.000 claims description 3
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 3
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 3
108010001127 Insulin Receptor Proteins 0.000 claims description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical class O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
108010029888 NIMA-Related Kinases Proteins 0.000 claims description 3
102000001783 NIMA-Related Kinases Human genes 0.000 claims description 3
229930012538 Paclitaxel Chemical class 0.000 claims description 3
229940079156 Proteasome inhibitor Drugs 0.000 claims description 3
108010042352 Urokinase Plasminogen Activator Receptors Chemical group 0.000 claims description 3
102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 claims description 3
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 3
229960001220 amsacrine Drugs 0.000 claims description 3
229960002932 anastrozole Drugs 0.000 claims description 3
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical group N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 3
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 3
229960000397 bevacizumab Drugs 0.000 claims description 3
229960000997 bicalutamide Drugs 0.000 claims description 3
BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical group B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 claims description 3
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
229960001467 bortezomib Drugs 0.000 claims description 3
229960002092 busulfan Drugs 0.000 claims description 3
229960004562 carboplatin Drugs 0.000 claims description 3
229960005395 cetuximab Drugs 0.000 claims description 3
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
229960004630 chlorambucil Drugs 0.000 claims description 3
229960004397 cyclophosphamide Drugs 0.000 claims description 3
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical group C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 3
229960000978 cyproterone acetate Drugs 0.000 claims description 3
229960000640 dactinomycin Drugs 0.000 claims description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 3
229960003668 docetaxel Drugs 0.000 claims description 3
229960004679 doxorubicin Drugs 0.000 claims description 3
229950004203 droloxifene Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
229960001904 epirubicin Drugs 0.000 claims description 3
229930013356 epothilone Chemical class 0.000 claims description 3
150000003883 epothilone derivatives Chemical class 0.000 claims description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
229960005420 etoposide Drugs 0.000 claims description 3
229960000255 exemestane Drugs 0.000 claims description 3
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical group N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 3
229960004039 finasteride Drugs 0.000 claims description 3
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical group CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
229960002074 flutamide Drugs 0.000 claims description 3
229960003690 goserelin acetate Drugs 0.000 claims description 3
239000003966 growth inhibitor Substances 0.000 claims description 3
229960000908 idarubicin Drugs 0.000 claims description 3
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
229960001101 ifosfamide Drugs 0.000 claims description 3
239000000367 immunologic factor Substances 0.000 claims description 3
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
229960004768 irinotecan Drugs 0.000 claims description 3
229960003881 letrozole Drugs 0.000 claims description 3
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
229960004296 megestrol acetate Drugs 0.000 claims description 3
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical group C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 3
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
229960001924 melphalan Drugs 0.000 claims description 3
239000003475 metalloproteinase inhibitor Chemical group 0.000 claims description 3
229960000485 methotrexate Drugs 0.000 claims description 3
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 3
229960004857 mitomycin Drugs 0.000 claims description 3
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical group C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims description 3
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical group O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 3
229960002653 nilutamide Drugs 0.000 claims description 3
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 3
229960001592 paclitaxel Drugs 0.000 claims description 3
229960003171 plicamycin Drugs 0.000 claims description 3
239000003207 proteasome inhibitor Substances 0.000 claims description 3
229960004622 raloxifene Drugs 0.000 claims description 3
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical group C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
239000012453 solvate Substances 0.000 claims description 3
229960001603 tamoxifen Drugs 0.000 claims description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical class O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
229960001278 teniposide Drugs 0.000 claims description 3
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
229960000303 topotecan Drugs 0.000 claims description 3
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical group C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 3
229960005026 toremifene Drugs 0.000 claims description 3
229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical class C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims description 3
229960000922 vinflunine Drugs 0.000 claims description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Chemical class O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
229950010817 alvocidib Drugs 0.000 claims description 2
BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims description 2
229940043355 kinase inhibitor Drugs 0.000 claims description 2
239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical class C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical class C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
229960004528 vincristine Drugs 0.000 claims description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical class C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
229960002066 vinorelbine Drugs 0.000 claims description 2
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical group C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims 2
102000003746 Insulin Receptor Human genes 0.000 claims 2
150000003838 adenosines Chemical class 0.000 claims 2
229960002949 fluorouracil Drugs 0.000 claims 2
125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 2
229960004961 mechlorethamine Drugs 0.000 claims 2
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 1
XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical class C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 claims 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 10
230000001028 anti-proliverative effect Effects 0.000 abstract description 9
101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 abstract 1
102000001301 EGF receptor Human genes 0.000 abstract 1
101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 abstract 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 72
239000000203 mixture Substances 0.000 description 67
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
239000000243 solution Substances 0.000 description 49
KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 41
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 31
239000011541 reaction mixture Substances 0.000 description 29
239000000047 product Substances 0.000 description 28
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
239000007787 solid Substances 0.000 description 26
238000006243 chemical reaction Methods 0.000 description 25
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
239000000725 suspension Substances 0.000 description 24
238000004128 high performance liquid chromatography Methods 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
235000019439 ethyl acetate Nutrition 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
238000002360 preparation method Methods 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
238000001914 filtration Methods 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
235000012771 pancakes Nutrition 0.000 description 15
125000004432 carbon atom Chemical group C* 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 13
239000003921 oil Substances 0.000 description 13
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
235000019198 oils Nutrition 0.000 description 11
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 11
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
229910052736 halogen Inorganic materials 0.000 description 10
150000002367 halogens Chemical class 0.000 description 10
239000010410 layer Substances 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
125000003545 alkoxy group Chemical group 0.000 description 9
238000001035 drying Methods 0.000 description 9
125000000623 heterocyclic group Chemical group 0.000 description 9
239000002904 solvent Substances 0.000 description 9
125000001424 substituent group Chemical group 0.000 description 9
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
125000004494 ethyl ester group Chemical group 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
150000007513 acids Chemical class 0.000 description 7
150000001414 amino alcohols Chemical class 0.000 description 7
235000014113 dietary fatty acids Nutrition 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
150000004665 fatty acids Chemical class 0.000 description 7
239000012071 phase Substances 0.000 description 7
125000003386 piperidinyl group Chemical group 0.000 description 7
101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 6
125000003282 alkyl amino group Chemical group 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
239000002585 base Substances 0.000 description 6
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
239000007859 condensation product Substances 0.000 description 6
239000003814 drug Substances 0.000 description 6
235000003599 food sweetener Nutrition 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
238000000746 purification Methods 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
230000011664 signaling Effects 0.000 description 6
239000003765 sweetening agent Substances 0.000 description 6
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
101001123846 Homo sapiens Serine/threonine-protein kinase Nek1 Proteins 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
102100028751 Serine/threonine-protein kinase Nek1 Human genes 0.000 description 5
125000005236 alkanoylamino group Chemical group 0.000 description 5
125000004390 alkyl sulfonyl group Chemical group 0.000 description 5
125000004414 alkyl thio group Chemical group 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
125000001589 carboacyl group Chemical group 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000007789 gas Substances 0.000 description 5
125000004537 indazol-5-yl group Chemical group N1N=CC2=CC(=CC=C12)* 0.000 description 5
230000014759 maintenance of location Effects 0.000 description 5
125000002757 morpholinyl group Chemical group 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
125000000335 thiazolyl group Chemical group 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
102000001253 Protein Kinase Human genes 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
125000004423 acyloxy group Chemical group 0.000 description 4
125000003342 alkenyl group Chemical group 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 4
238000009835 boiling Methods 0.000 description 4
125000002837 carbocyclic group Chemical group 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
125000004663 dialkyl amino group Chemical group 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
239000000945 filler Substances 0.000 description 4
239000000834 fixative Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
125000002541 furyl group Chemical group 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
150000002431 hydrogen Chemical class 0.000 description 4
125000004356 hydroxy functional group Chemical group O* 0.000 description 4
125000002883 imidazolyl group Chemical group 0.000 description 4
239000004530 micro-emulsion Substances 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
238000010899 nucleation Methods 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
239000000049 pigment Substances 0.000 description 4
210000002307 prostate Anatomy 0.000 description 4
108060006633 protein kinase Proteins 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
125000000714 pyrimidinyl group Chemical group 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
150000005846 sugar alcohols Polymers 0.000 description 4
239000003826 tablet Substances 0.000 description 4
125000001544 thienyl group Chemical group 0.000 description 4
150000003573 thiols Chemical class 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 3
KACWEIWGSHNESJ-UHFFFAOYSA-N 1-benzyl-5-nitroindazole Chemical compound N1=CC2=CC([N+](=O)[O-])=CC=C2N1CC1=CC=CC=C1 KACWEIWGSHNESJ-UHFFFAOYSA-N 0.000 description 3
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 3
WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
108010055325 EphB3 Receptor Proteins 0.000 description 3
102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
241000256856 Vespidae Species 0.000 description 3
SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000004913 activation Effects 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
125000001769 aryl amino group Chemical group 0.000 description 3
125000004104 aryloxy group Chemical group 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
239000002024 ethyl acetate extract Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
108091008598 receptor tyrosine kinases Proteins 0.000 description 3
102000027426 receptor tyrosine kinases Human genes 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 2
BQUSMTPKYUILPD-UHFFFAOYSA-N 1-benzylindazol-5-amine Chemical compound N1=CC2=CC(N)=CC=C2N1CC1=CC=CC=C1 BQUSMTPKYUILPD-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 2
XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical class NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 2
QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical class NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 description 2
BJKRRLWNBFNWNA-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]ethyl carbamate Chemical compound CN(C)CCOCCOC(N)=O BJKRRLWNBFNWNA-UHFFFAOYSA-N 0.000 description 2
OVSZLTGJLCLHER-UHFFFAOYSA-N 2-imidazol-1-ylethyl carbamate Chemical compound NC(=O)OCCN1C=CN=C1 OVSZLTGJLCLHER-UHFFFAOYSA-N 0.000 description 2
NIASUEKXVYKUAO-UHFFFAOYSA-N 2-morpholin-4-ylethyl carbamate Chemical compound NC(=O)OCCN1CCOCC1 NIASUEKXVYKUAO-UHFFFAOYSA-N 0.000 description 2
NNPKNULBDCHAMV-UHFFFAOYSA-N 2-piperidin-1-ylethyl carbamate Chemical compound NC(=O)OCCN1CCCCC1 NNPKNULBDCHAMV-UHFFFAOYSA-N 0.000 description 2
DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 description 2
MBSJSCARNZBIEZ-UHFFFAOYSA-N 3-piperazin-1-ylpropyl carbamate Chemical compound NC(=O)OCCCN1CCNCC1 MBSJSCARNZBIEZ-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
VMPCLAPFFPTHJT-UHFFFAOYSA-N C(N)(OCCC=1C=NC=CC=1)=O Chemical compound C(N)(OCCC=1C=NC=CC=1)=O VMPCLAPFFPTHJT-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000005662 Paraffin oil Substances 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
108091005682 Receptor kinases Proteins 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
125000001691 aryl alkyl amino group Chemical group 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
229910052796 boron Inorganic materials 0.000 description 2
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
239000000460 chlorine Chemical group 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
210000003128 head Anatomy 0.000 description 2
238000005734 heterodimerization reaction Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052740 iodine Chemical group 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
210000003739 neck Anatomy 0.000 description 2
208000004995 necrotizing enterocolitis Diseases 0.000 description 2
201000002120 neuroendocrine carcinoma Diseases 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000012053 oil suspension Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
150000003921 pyrrolotriazines Chemical class 0.000 description 2
BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
235000011069 sorbitan monooleate Nutrition 0.000 description 2
239000001593 sorbitan monooleate Substances 0.000 description 2
229940035049 sorbitan monooleate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000005017 substituted alkenyl group Chemical group 0.000 description 2
125000004426 substituted alkynyl group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
AIQSXVGBMCJQAG-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1CO AIQSXVGBMCJQAG-UHFFFAOYSA-N 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
XIPCNOINPJBEGO-UHFFFAOYSA-N (4-hydroxy-1-methylcyclohexyl)carbamic acid Chemical compound OC(=O)NC1(C)CCC(O)CC1 XIPCNOINPJBEGO-UHFFFAOYSA-N 0.000 description 1
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
LLZBPZWEHUQJKO-UHFFFAOYSA-N 1,1-bis(2-methoxyethyl)urea Chemical compound COCCN(C(N)=O)CCOC LLZBPZWEHUQJKO-UHFFFAOYSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
UPTZBFZYNZFJEN-UHFFFAOYSA-N 2-(hydroxymethyl)piperidine-1-carboxylic acid Chemical class OCC1CCCCN1C(O)=O UPTZBFZYNZFJEN-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
ONOBHKWISLHHCC-UHFFFAOYSA-N 2-benzyl-5-nitroindazole Chemical class C1=C2C=C([N+](=O)[O-])C=CC2=NN1CC1=CC=CC=C1 ONOBHKWISLHHCC-UHFFFAOYSA-N 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
IHCDQQHNHQCALV-UHFFFAOYSA-N 2-methoxyethylurea Chemical compound COCCNC(N)=O IHCDQQHNHQCALV-UHFFFAOYSA-N 0.000 description 1
125000004635 2-oxazepinyl group Chemical group O1N(CC=CC=C1)* 0.000 description 1
125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
GIYNSTWNEVPSJT-UHFFFAOYSA-N 3-(hydroxymethyl)piperidine-1-carboxylic acid Chemical compound OCC1CCCN(C(O)=O)C1 GIYNSTWNEVPSJT-UHFFFAOYSA-N 0.000 description 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
OWIRCRREDNEXTA-UHFFFAOYSA-N 3-nitro-1h-indazole Chemical compound C1=CC=C2C([N+](=O)[O-])=NNC2=C1 OWIRCRREDNEXTA-UHFFFAOYSA-N 0.000 description 1
OCBBIXPJQUQZDM-UHFFFAOYSA-N 4-(2-hydroxyethyl)piperidine-1-carboxylic acid Chemical compound OCCC1CCN(C(O)=O)CC1 OCBBIXPJQUQZDM-UHFFFAOYSA-N 0.000 description 1
UGYAVIIKOVRYMK-UHFFFAOYSA-N 4-amino-1-methylpiperidin-3-ol Chemical compound CN1CCC(N)C(O)C1 UGYAVIIKOVRYMK-UHFFFAOYSA-N 0.000 description 1
RKTQEVMZBCBOSB-UHFFFAOYSA-N 4-aminocyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1CCC(O)CC1 RKTQEVMZBCBOSB-UHFFFAOYSA-N 0.000 description 1
125000005986 4-piperidonyl group Chemical group 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
102400001242 Betacellulin Human genes 0.000 description 1
101800001382 Betacellulin Proteins 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
244000056139 Brassica cretica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001329 Epiregulin Human genes 0.000 description 1
101800000155 Epiregulin Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 1
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
101000601460 Homo sapiens Serine/threonine-protein kinase Nek4 Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100036721 Insulin receptor Human genes 0.000 description 1
102400001355 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
150000000994 L-ascorbates Chemical class 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
ODLJRUWWCGEVPV-UHFFFAOYSA-N N1=NNC2=CC=NC2=C1Cl Chemical compound N1=NNC2=CC=NC2=C1Cl ODLJRUWWCGEVPV-UHFFFAOYSA-N 0.000 description 1
102000014413 Neuregulin Human genes 0.000 description 1
108050003475 Neuregulin Proteins 0.000 description 1
102400000058 Neuregulin-1 Human genes 0.000 description 1
108090000556 Neuregulin-1 Proteins 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
208000007256 Nevus Diseases 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
YQXQEGIOBJAABC-IZLXSQMJSA-N O[C@H]1CC[C@H](NC(O)=O)CC1 Chemical compound O[C@H]1CC[C@H](NC(O)=O)CC1 YQXQEGIOBJAABC-IZLXSQMJSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
102100037705 Serine/threonine-protein kinase Nek4 Human genes 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
FRWNOIPPJXCANT-UHFFFAOYSA-N [4-(2-hydroxyethyl)piperazin-1-yl]carbamic acid Chemical compound OCCN1CCN(NC(O)=O)CC1 FRWNOIPPJXCANT-UHFFFAOYSA-N 0.000 description 1
OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 description 1
FIQIEWYXLLEXNR-UHFFFAOYSA-N [O-][N+](=O)S(=O)(=O)[N+]([O-])=O Chemical compound [O-][N+](=O)S(=O)(=O)[N+]([O-])=O FIQIEWYXLLEXNR-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
230000001740 anti-invasion Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
125000005239 aroylamino group Chemical group 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000004659 aryl alkyl thio group Chemical group 0.000 description 1
125000002102 aryl alkyloxo group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
GFVNJDIBQYYKGS-UHFFFAOYSA-N azetidin-3-yl carbamate Chemical compound NC(=O)OC1CNC1 GFVNJDIBQYYKGS-UHFFFAOYSA-N 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
125000006267 biphenyl group Chemical group 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
244000275904 brauner Senf Species 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
210000005266 circulating tumour cell Anatomy 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000000571 coke Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
125000006001 difluoroethyl group Chemical group 0.000 description 1
125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000000539 dimer Substances 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000000286 epitheliocyte Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
150000005699 fluoropyrimidines Chemical class 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000005179 haloacetyl group Chemical group 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
229940116978 human epidermal growth factor Drugs 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
239000012535 impurity Substances 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000011630 iodine Chemical group 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000003971 isoxazolinyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
229950008959 marimastat Drugs 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
NDBQJIBNNUJNHA-DFWYDOINSA-N methyl (2s)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CO NDBQJIBNNUJNHA-DFWYDOINSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229960005419 nitrogen Drugs 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000005416 organic matter Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FMCPHGPMGDIHMK-UHFFFAOYSA-N oxan-4-yl carbamate Chemical compound NC(=O)OC1CCOCC1 FMCPHGPMGDIHMK-UHFFFAOYSA-N 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
PRAYXGYYVXRDDW-UHFFFAOYSA-N piperidin-2-ylmethanol Chemical compound OCC1CCCCN1 PRAYXGYYVXRDDW-UHFFFAOYSA-N 0.000 description 1
BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
KCYQSFOCCXSZQY-UHFFFAOYSA-N piperidin-4-yl carbamate Chemical compound NC(=O)OC1CCNCC1 KCYQSFOCCXSZQY-UHFFFAOYSA-N 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000006513 pyridinyl methyl group Chemical group 0.000 description 1
125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
BEBRHYJBTAMGRW-UHFFFAOYSA-N pyrrolo[3,2-d]triazin-4-one Chemical compound O=C1N=NN=C2C=CN=C12 BEBRHYJBTAMGRW-UHFFFAOYSA-N 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
229960000460 razoxane Drugs 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000025053 regulation of cell proliferation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000003900 succinic acid esters Chemical class 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003899 tartaric acid esters Chemical class 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
PZTAGFCBNDBBFZ-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CO PZTAGFCBNDBBFZ-UHFFFAOYSA-N 0.000 description 1
CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 1
SBWYTQQSTIUXOP-UHFFFAOYSA-N tert-butyl n-(1-hydroxy-2-methylpropan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)CO SBWYTQQSTIUXOP-UHFFFAOYSA-N 0.000 description 1
DQARDWKWPIRJEH-UHFFFAOYSA-N tert-butyl n-(4-hydroxycyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(O)CC1 DQARDWKWPIRJEH-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000004589 thienofuryl group Chemical group O1C(=CC2=C1C=CS2)* 0.000 description 1
125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
125000002053 thietanyl group Chemical group 0.000 description 1
125000001730 thiiranyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Inks, Pencil-Leads, Or Crayons (AREA)

UAA200506891A 2002-12-13 2003-12-12 C-6 modificated indazolilpyrrolotriazines, pharmaceutical composition upon their base and method of the treatment UA80591C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43319002P	2002-12-13	2002-12-13
PCT/US2003/039542 WO2004054514A2 (en)	2002-12-13	2003-12-12	C-6 modified indazolylpyrrolotriazines

Publications (1)

Publication Number	Publication Date
UA80591C2 true UA80591C2 (en)	2007-10-10

Family

ID=32595133

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200506891A UA80591C2 (en)	2002-12-13	2003-12-12	C-6 modificated indazolilpyrrolotriazines, pharmaceutical composition upon their base and method of the treatment

Country Status (27)

Country	Link
US (2)	US6916815B2 (is)
EP (1)	EP1569937B1 (is)
JP (1)	JP4511367B2 (is)
KR (1)	KR101073801B1 (is)
CN (2)	CN101723948A (is)
AR (1)	AR042450A1 (is)
AT (1)	ATE534648T1 (is)
AU (1)	AU2003300877B2 (is)
BR (1)	BR0316755A (is)
CA (1)	CA2509650C (is)
CO (1)	CO5570660A2 (is)
DK (1)	DK1569937T3 (is)
ES (1)	ES2374393T3 (is)
HR (1)	HRP20050535A2 (is)
IS (1)	IS7890A (is)
MX (1)	MXPA05006164A (is)
NO (1)	NO20052733L (is)
NZ (1)	NZ540338A (is)
PE (1)	PE20040805A1 (is)
PL (1)	PL377517A1 (is)
PT (1)	PT1569937E (is)
RS (1)	RS20050441A (is)
RU (1)	RU2356903C2 (is)
TW (1)	TW200420565A (is)
UA (1)	UA80591C2 (is)
WO (1)	WO2004054514A2 (is)
ZA (1)	ZA200504507B (is)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69734362T2 (de) *	1996-12-03	2006-07-20	Sloan-Kettering Institute For Cancer Research	Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
US7625859B1 (en)	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20090197852A9 (en) *	2001-08-06	2009-08-06	Johnson Robert G Jr	Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
JP4669225B2 (ja)	2002-04-23	2011-04-13	ブリストル−マイヤーズスクイブカンパニー	キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物
AU2003221753A1 (en)	2002-04-23	2003-11-10	Bristol-Myers Squibb Company	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
TWI329112B (en) *	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
ES2281692T3 (es)	2002-08-23	2007-10-01	Sloan-Kettering Institute For Cancer Research	Sintesis de epotilones, sus intermediarios, sus analogos y sus usos.
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
BRPI0407282A (pt)	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase
EP2641611A3 (en) *	2003-10-17	2013-12-18	Novo Nordisk A/S	Combination therapy
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7064203B2 (en) *	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7173031B2 (en)	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es)	2004-08-12	2006-06-01	Bristol Myers Squibb Co	Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
AU2005294347A1 (en) *	2004-10-05	2006-04-20	Oregon Health And Science University	Compositions and methods for treating disease
US7151176B2 (en) *	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
RU2412199C2 (ru)	2005-04-18	2011-02-20	Ново Нордиск А/С	Варианты ил-21
US7402582B2 (en) *	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007035428A1 (en)	2005-09-15	2007-03-29	Bristol-Myers Squibb Company	Met kinase inhibitors
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
EP2001886A2 (en)	2006-03-07	2008-12-17	Bristol-Myers Squibb Company	Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
CA2666426A1 (en)	2006-10-26	2008-05-02	Novo Nordisk A/S	Il-21 variants
WO2008074863A1 (en) *	2006-12-21	2008-06-26	Novo Nordisk A/S	Interleukin-21 variants with altered binding to the il-21 receptor
US20090083483A1 (en) *	2007-09-24	2009-03-26	International Business Machines Corporation	Power Conservation In A RAID Array
US8166326B2 (en) *	2007-11-08	2012-04-24	International Business Machines Corporation	Managing power consumption in a computer
US20090132842A1 (en) *	2007-11-15	2009-05-21	International Business Machines Corporation	Managing Computer Power Consumption In A Computer Equipment Rack
US8041521B2 (en) *	2007-11-28	2011-10-18	International Business Machines Corporation	Estimating power consumption of computing components configured in a computing system
CA2719362A1 (en) *	2008-04-04	2009-10-08	Gilead Sciences, Inc.	Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
WO2009137201A1 (en)	2008-04-04	2009-11-12	Cv Therapeutics, Inc.	Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
WO2009126311A1 (en) *	2008-04-11	2009-10-15	The University Of Texas, M.D. Anderson Cancer Center	Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
US8103884B2 (en)	2008-06-25	2012-01-24	International Business Machines Corporation	Managing power consumption of a computer
US8041976B2 (en) *	2008-10-01	2011-10-18	International Business Machines Corporation	Power management for clusters of computers
US8514215B2 (en) *	2008-11-12	2013-08-20	International Business Machines Corporation	Dynamically managing power consumption of a computer with graphics adapter configurations
AR074830A1 (es)	2008-12-19	2011-02-16	Cephalon Inc	Pirrolotriazinas como inhibidores de alk y jak2
CA2754909A1 (en) *	2009-03-11	2010-09-16	Ambit Biosciences Corp.	Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2011112689A2 (en)	2010-03-11	2011-09-15	Ambit Biosciences Corp.	Saltz of an indazolylpyrrolotriazine
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9403834B2 (en) *	2013-03-11	2016-08-02	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
EP2970295B1 (en) *	2013-03-11	2016-12-28	Bristol-Myers Squibb Company	Pyrrolopyridazines as potassium ion channel inhibitors
US9050345B2 (en) *	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
WO2015081783A1 (zh) *	2013-12-06	2015-06-11	江苏奥赛康药业股份有限公司	吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
CN111533708B (zh) *	2020-06-12	2021-03-16	上海馨远医药科技有限公司	一种手性n-叔丁氧羰基吗啉-3-羧酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4908056A (en) *	1986-04-25	1990-03-13	E. I. Du Pont De Nemours And Company	Heterocyclic acyl sulfonamides
DK0778277T3 (da)	1995-12-08	2003-10-27	Pfizer	Substituerede heterocycliske derivater som CRF antagonister
CN1227554A (zh)	1996-08-28	1999-09-01	辉瑞大药厂	取代的6,5－杂二环衍生物
AU770377B2 (en) *	1999-05-21	2004-02-19	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
JP4623483B2 (ja)	1999-08-23	2011-02-02	塩野義製薬株式会社	ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
HRP20030485A2 (en) *	2000-11-17	2004-08-31	Bristol Myers Squibb Co	METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
AU2003221753A1 (en)	2002-04-23	2003-11-10	Bristol-Myers Squibb Company	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
JP4669225B2 (ja)	2002-04-23	2011-04-13	ブリストル−マイヤーズスクイブカンパニー	キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine

2003
- 2003-12-08 TW TW092134601A patent/TW200420565A/zh unknown
- 2003-12-12 AT AT03813396T patent/ATE534648T1/de active
- 2003-12-12 DK DK03813396.3T patent/DK1569937T3/da active
- 2003-12-12 MX MXPA05006164A patent/MXPA05006164A/es active IP Right Grant
- 2003-12-12 RU RU2005120650/04A patent/RU2356903C2/ru not_active IP Right Cessation
- 2003-12-12 RS YUP-2005/0441A patent/RS20050441A/sr unknown
- 2003-12-12 PT PT03813396T patent/PT1569937E/pt unknown
- 2003-12-12 PE PE2003001275A patent/PE20040805A1/es not_active Application Discontinuation
- 2003-12-12 CA CA002509650A patent/CA2509650C/en not_active Expired - Fee Related
- 2003-12-12 WO PCT/US2003/039542 patent/WO2004054514A2/en not_active Ceased
- 2003-12-12 CN CN200910246410A patent/CN101723948A/zh active Pending
- 2003-12-12 UA UAA200506891A patent/UA80591C2/uk unknown
- 2003-12-12 PL PL377517A patent/PL377517A1/pl not_active Application Discontinuation
- 2003-12-12 KR KR1020057010549A patent/KR101073801B1/ko not_active Expired - Fee Related
- 2003-12-12 HR HR20050535A patent/HRP20050535A2/hr not_active Application Discontinuation
- 2003-12-12 AU AU2003300877A patent/AU2003300877B2/en not_active Ceased
- 2003-12-12 CN CNA200380105906XA patent/CN1726216A/zh active Pending
- 2003-12-12 EP EP03813396A patent/EP1569937B1/en not_active Expired - Lifetime
- 2003-12-12 JP JP2004560804A patent/JP4511367B2/ja not_active Expired - Fee Related
- 2003-12-12 BR BR0316755-0A patent/BR0316755A/pt not_active IP Right Cessation
- 2003-12-12 ES ES03813396T patent/ES2374393T3/es not_active Expired - Lifetime
- 2003-12-12 AR ARP030104592A patent/AR042450A1/es unknown
- 2003-12-12 NZ NZ540338A patent/NZ540338A/en not_active IP Right Cessation
- 2003-12-15 US US10/736,476 patent/US6916815B2/en not_active Expired - Fee Related
2005
- 2005-06-01 ZA ZA200504507A patent/ZA200504507B/en unknown
- 2005-06-02 US US11/143,279 patent/US7148220B2/en not_active Expired - Fee Related
- 2005-06-07 NO NO20052733A patent/NO20052733L/no not_active Application Discontinuation
- 2005-06-10 IS IS7890A patent/IS7890A/is unknown
- 2005-06-13 CO CO05057043A patent/CO5570660A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2005120650A (ru)	2006-01-20
US20040142931A1 (en)	2004-07-22
RS20050441A (sr)	2007-04-10
EP1569937A4 (en)	2007-08-08
CN1726216A (zh)	2006-01-25
ATE534648T1 (de)	2011-12-15
NZ540338A (en)	2008-05-30
BR0316755A (pt)	2005-10-25
AU2003300877B2 (en)	2010-02-18
JP2006509826A (ja)	2006-03-23
ES2374393T3 (es)	2012-02-16
RU2356903C2 (ru)	2009-05-27
NO20052733L (no)	2005-07-07
PT1569937E (pt)	2012-01-04
PL377517A1 (pl)	2006-02-06
HRP20050535A2 (en)	2005-12-31
TW200420565A (en)	2004-10-16
AR042450A1 (es)	2005-06-22
IS7890A (is)	2005-06-10
US20050222153A1 (en)	2005-10-06
US7148220B2 (en)	2006-12-12
ZA200504507B (en)	2006-08-30
DK1569937T3 (da)	2012-01-02
CA2509650A1 (en)	2004-07-01
KR101073801B1 (ko)	2011-10-13
EP1569937B1 (en)	2011-11-23
MXPA05006164A (es)	2005-08-26
EP1569937A2 (en)	2005-09-07
JP4511367B2 (ja)	2010-07-28
CA2509650C (en)	2007-10-30
US6916815B2 (en)	2005-07-12
WO2004054514A3 (en)	2004-10-07
WO2004054514A2 (en)	2004-07-01
AU2003300877A1 (en)	2004-07-09
NO20052733D0 (no)	2005-06-07
KR20050084242A (ko)	2005-08-26
CO5570660A2 (es)	2005-10-31
CN101723948A (zh)	2010-06-09
PE20040805A1 (es)	2004-11-20

Publication	Publication Date	Title
UA80591C2 (en)	2007-10-10	C-6 modificated indazolilpyrrolotriazines, pharmaceutical composition upon their base and method of the treatment
RU2677667C2 (ru)	2019-01-18	Соединения n-пирролидинилмочевины, n'-пиразолилмочевины, тиомочевины, гуанидина и цианогуанидина как ингибиторы киназы trka
KR102553188B1 (ko)	2023-07-11	신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸
CN116589466B (zh)	2025-08-15	通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
AU2007239498B2 (en)	2012-08-23	Trisubstituted 1,2,4-triazoles
US20230265116A1 (en)	2023-08-24	Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
AU2017289315B2 (en)	2021-04-01	Heteroaromatic derivatives as NIK inhibitors
JP2010536869A (ja)	2010-12-02	ナフチルピリミジン、ナフチルピラジンおよびナフチルピリダジン類似体、ならびにＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
EP2559693A1 (en)	2013-02-20	Polycyclic compound
IL269933B (en)	2022-07-01	Benzozapine analogues as inhibitors for proton tyrosine kinase
EA029842B1 (ru)	2018-05-31	2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
CN106608879A (zh)	2017-05-03	一种蛋白激酶抑制剂及其制备方法和医药用途
MD4161927T2 (ro)	2024-11-30	Compuși spiro în calitate de antagoniști ai receptorului de melanocortină 4 și utilizările acestora
US20230399327A1 (en)	2023-12-14	High activity hpk1 kinase inhibitor
AU2022265323B2 (en)	2024-05-16	Heterocyclic compounds capable of activating sting
EP4615850A1 (en)	2025-09-17	Compounds for the degradation of egfr kinase
CA2882410A1 (en)	2014-03-27	Dihydropyrrolidino-pyrimidines as kinase inhibitors
AU2024281173A1 (en)	2025-12-04	Compounds for the degradation of egfr kinase
AU2019350717B2 (en)	2025-05-29	Aminopyrimidine compound
KR20050113218A (ko)	2005-12-01	치환된 2-(디아자-비시클로-알킬)-피리미돈 유도체
HK40123006A (zh)	2025-10-10	Ikzf2降解剂及其用途
EA048136B1 (ru)	2024-10-28	Спиросоединения в качестве антагонистов рецептора меланокортина 4 и их применения
CA3159250A1 (en)	2021-06-03	New compounds for treatment of diseases related to dux4 expression
EA047837B1 (ru)	2024-09-18	Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона